ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.02
+38.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 645.8K | 815.4K | 2.5M | 58.5K | — |
| Cost of Revenue | 126.6K | 182.5K | 1.5M | 1.2M | 6.8K |
| Gross Profit | 519.2K | 632.9K | 1.1M | (1.1M) | (6.8K) |
| Operating Expenses | |||||
| R&D Expense | 75.3K | (66.1K) | 154.4K | 1.9M | 4.1M |
| SG&A Expense | 8.1M | 7.0M | 11.2M | 14.8M | 9.4M |
| General & Admin Expense | — | 7.0M | 11.2M | 14.8M | 9.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 486.0K | — | 46.2M | 18.2M | — |
| Total Operating Expenses | 8.7M | 7.0M | 57.5M | 34.9M | 13.5M |
| Cost and Expenses | 8.8M | 7.2M | 59.0M | 36.1M | 13.5M |
| Operating Income (EBIT) | (8.2M) | (6.3M) | (56.5M) | (36.0M) | (13.5M) |
| Non-Operating | |||||
| Interest Income | — | — | 18.00 | — | — |
| Interest Expense | 310.9K | 751.0K | 1.4M | 671.6K | — |
| Net Interest Income | (310.9K) | (751.0K) | (1.4M) | (671.6K) | — |
| Other Non-Op Income/Expense | (2.0M) | (7.7M) | (3.2M) | (1.4M) | 61.4K |
| Non-Operating Income (excl Interest) | 1.7M | 6.9M | 1.8M | 716.1K | (61.4K) |
| EBT (Pre-Tax Income) | (10.2M) | (14.0M) | (59.7M) | (37.4M) | (13.4M) |
| Income Tax Expense | 525.00 | 525.00 | (1.0M) | (12.6K) | — |
| Bottom Line | |||||
| Net Income | (10.2M) | (14.0M) | (58.7M) | (37.4M) | (13.4M) |
| Earnings from Cont. Ops | (10.2M) | (14.0M) | (58.7M) | (37.4M) | (13.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.2M) | (15.5M) | (58.9M) | (37.4M) | (13.5M) |
| Per Share | |||||
| Basic EPS | ($8.74) | ($4.73) | ($520.93) | ($25.03) | ($0.31) |
| Diluted EPS | ($8.74) | ($4.73) | ($520.93) | ($25.03) | ($0.31) |
| Revenue Per Share | $0.29 | $0.25 | $22.33 | $3.32 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 2.2M | 3.3M | 113050 | 17612 | 12632 |
| Diluted Shares Outstanding | 2.2M | 3.3M | 113050 | 17612 | 12632 |
| Profitability Metrics | |||||
| EBITDA | (9.9M) | (13.3M) | (57.6M) | (36.7M) | (13.4M) |
| D&A | 12.1K | 15.2K | 731.3K | 43.9K | 6.8K |
| EBIT | (9.9M) | (13.3M) | (58.3M) | (36.8M) | (13.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026